ArticlePharmaceuticals (Basel, Switzerland)2024
Anti-Cholinergic Effects of the Phenolic Extract from the
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Mechanistic convergence ofIBRO neuroscience reports · 2026Article
- Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.Materials today. Bio · 2026Article
- Integrated Morphological, Molecular, and Chemical Characterization of the Macrofungus Pholiota Gallica With Phylogenetic Analysis and in Silico Antioxidant and Anti-Inflammatory Evaluation.Chemistry & biodiversity · 2026Article
- Phytochemical Profiling and Antioxidant Properties ofPlants (Basel, Switzerland) · 2026Article
- Chemical Profiling and Multi-Target Bioactivities of Erodium guttatum From Northeastern Algeria: LC-MS/MS and Molecular Docking Insights.Chemistry & biodiversity · 2026Article
- Chemical Profile and Evaluation of the Antioxidant, Anti-Enzymatic, and Antibacterial Activity ofPlants (Basel, Switzerland) · 2025Article
- Metabolite Profiling and Bioactivity of Eastern AlgerianACS omega · 2025Article
- Corchorus olitorius exhibits antiproliferative potential supported by metabolic profiling and integrative biological analyses.Scientific reports · 2025Article
- A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation.Scientific reports · 2025Article
- Silymarin as a Therapeutic Agent for Hepatocellular Carcinoma: A Multi-Approach Computational Study.Metabolites · 2025Article
- Bioactive Phenolics ofInternational journal of molecular sciences · 2025Article
- Preliminary Data onMetabolites · 2025Article
- From Green Chemistry to Healthy Environments: Silver Nanoparticles as a Dual Antioxidant and Antibacterial Agents for Advancing Biomedicine and Sustainable Wastewater Treatment.Bioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Investigations into cholinesterase inhibition have received attention from researchers in recent years for the treatment of Alzheimer's disease. Cholinesterase enzymes, namely, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), hold pivotal significance in Alzheimer's disease (AD) treatment. In this study, we utilized the ethanolic extract of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.